

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Status: RECRUITING

Eligibility Criteria

Sex: ALL

Age:

Healthy Volunteers: This study is NOT accepting healthy volunteers

Inclusion Criteria:

- All patients undergoing allogeneic HSCT at our institution will be evaluated for graft rejection risk factors. Patients deemed high risk for graft rejection will have 2 or more of the following: mismatched or haploidentical donor, ex vivo t-cell depleted graft, prior history of graft rejection.

Exclusion Criteria:

- Known hypersensitivity to any constituent of the study medication.

Conditions & Interventions

Interventions:

DRUG: Emapalumab 3 mg/kg, DRUG: Emapalumab 10 mg/kg

Conditions:

Hematopoietic Stem Cell Transplantation, Graft Failure

More Information

Description:

The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.

Contact(s): Jessica Anderson - jessica.anderson@cchmc.org

Principal Investigator:

Principal Investigator ID:

Phase: EARLY_PHASE1

IRB Number:

System ID: NCT07244419

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cchmc.org> to find a Study which is right for you and contact clinicalstudies@cchmc.org if you have questions or need assistance.